Cue Biopharma vs Janux Therapeutics
CUE and JANX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and JANX compare
Janux Therapeutics is the larger company, worth 5.6 times as much as Cue Biopharma ($757M against $136M).
Cue Biopharma grew revenue faster over the last twelve months (354% versus 133% for Janux Therapeutics).
Janux Therapeutics keeps more of each dollar of sales as profit, with a net margin of −429% compared with −436% at Cue Biopharma.
Janux Therapeutics scores higher on the StockData Score (10 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | JANX |
|---|---|---|
| Size and price | ||
| Market cap | $136M | $757M |
| Share price | $18.66 | $12.39 |
| Change, 1 year | −8.7% | −55.1% |
| Change, 5 years | −95.8% | −30.7% |
| Beta (5Y) | 2.37 | 1.63 |
| Employees | 29 | 109 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 32.5× |
| P/B | 58.7× | 0.8× (better) |
| FCF yield | −37.0% | −7.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 354% (better) | 133% |
| Revenue growth, 5Y average | 54.2% | – |
| Profitability | ||
| Operating margin | −262% (better) | −599% |
| Net margin | −436% | −429% (better) |
| FCF margin | −133% (better) | −233% |
| Return on equity | −1603% | −10.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.25 | 17.69 (better) |
| Altman Z-score | −30.32 | 6.37 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.6% | 101% |
| Held by insiders | 17.4% | 21.3% |
| Insider net buying, 12 months | −$2.3M | −$457K (better) |
| Short interest, % of float | 14.4% | 11.1% |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- JANX stock overview
- JANX income statement
- JANX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.